Healthcare Industry News: Ortho-Clinical Diagnostics
News Release - November 27, 2007
ImmunoGen, Inc. Hires John Tagliamonte as Vice President, Business DevelopmentCAMBRIDGE, Mass.--(HSMN NewsFeed)--ImmunoGen, Inc. (Nasdaq: IMGN ), a biopharmaceutical company that develops targeted anticancer therapeutics using its Tumor-Activated Prodrug (TAP) technology, today announced that Mr. John Tagliamonte has joined the Company as Vice President, Business Development.
“John brings extensive business development and partnering experience to ImmunoGen, and we are glad to welcome him to our team,” commented Mitchel Sayare, Chairman and CEO. “He has held senior positions in business development at several healthcare companies, and he will lead our activities to further expand the application of our TAP technology through additional collaborations with biotechnology and pharmaceutical companies.”
Mr. Tagliamonte was most recently Senior Director of Strategy and Corporate Development at Millipore Corporation, where he led strategy, M&A execution and integration, licensing and alliances. Prior to joining Millipore in 2005, Mr. Tagliamonte served as Vice President of Commercial Operations at Laureate Pharma, a private life sciences company based in Princeton, NJ. Previously, he was Director of Business Development and Strategic Planning of the Ortho-Clinical Diagnostics unit of Johnson & Johnson. Mr. Tagliamonte held additional positions in business development and product management at Perkin Elmer and Bio-Rad Laboratories and has held research positions at Collaborative Research and Dana-Farber Cancer Institute. He currently serves on the advisory board of directors at BioHelix, a molecular diagnostics firm. Mr. Tagliamonte received his M.B.A. from Boston College and a B.S. in Molecular Cell Biology from Tufts University.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer biopharmaceuticals. The Company’s proprietary TAP technology uses tumor-targeting antibodies to deliver a potent cell-killing agent specifically to cancer cells. Two TAP compounds wholly owned by ImmunoGen are in clinical testing – IMGN901 (huN901-DM1) and IMGN242 (huC242-DM4). Three TAP compounds are in clinical testing through ImmunoGen’s collaborations with other companies – AVE9633 and SAR3419, in development by sanofi-aventis, and T-DM1 (trastuzumab-DM1), in development by Genentech. Additionally, the naked antibody compound, AVE1642, is in development through the Company’s collaboration with sanofi-aventis. Multiple compounds are in research/preclinical development through ImmunoGen’s collaborations and internal programs.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.